The blood screening strategy by employing both HBsAg and anti-HBc detection combined with HBV NAT assay in some developed countries allows the detection of window-period infection, OBI, and HBV mutated strains possible to maximally ensure blood safety. This evidence concerns the gene BRD2 and infection.